Equities research analysts expect Syneos Health, Inc. (NASDAQ:SYNH) to post $0.74 earnings per share for the current quarter, according to Zacks. Six analysts have made estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $0.76 and the lowest estimate coming in at $0.70. Syneos Health posted earnings of $0.68 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 8.8%. The business is scheduled to report its next earnings report before the market opens on Thursday, April 29th.
On average, analysts expect that Syneos Health will report full-year earnings of $4.23 per share for the current fiscal year, with EPS estimates ranging from $4.17 to $4.26. For the next year, analysts expect that the company will post earnings of $4.88 per share, with EPS estimates ranging from $4.79 to $4.94. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Syneos Health.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Thursday, February 18th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Syneos Health had a return on equity of 10.02% and a net margin of 4.28%. The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.13 billion.
Shares of SYNH stock traded down $0.63 during trading hours on Friday, hitting $79.37. The stock had a trading volume of 1,026 shares, compared to its average volume of 896,000. Syneos Health has a one year low of $46.27 and a one year high of $81.35. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.06 and a quick ratio of 1.06. The stock’s 50-day moving average price is $75.57 and its two-hundred day moving average price is $68.43. The stock has a market capitalization of $8.27 billion, a price-to-earnings ratio of 43.96 and a beta of 1.85.
In other Syneos Health news, CEO Alistair Macdonald sold 17,398 shares of the company’s stock in a transaction on Thursday, April 1st. The stock was sold at an average price of $77.61, for a total transaction of $1,350,258.78. Following the completion of the sale, the chief executive officer now owns 231,907 shares in the company, valued at $17,998,302.27. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Michelle Keefe sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 31st. The stock was sold at an average price of $78.00, for a total value of $156,000.00. In the last ninety days, insiders have sold 4,758,587 shares of company stock worth $353,153,609. Insiders own 0.44% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue lifted its holdings in Syneos Health by 5.0% during the first quarter. State of Alaska Department of Revenue now owns 12,950 shares of the company’s stock worth $982,000 after buying an additional 614 shares during the period. Pacer Advisors Inc. increased its position in shares of Syneos Health by 11.3% in the 1st quarter. Pacer Advisors Inc. now owns 9,371 shares of the company’s stock valued at $711,000 after acquiring an additional 952 shares during the period. Fulton Bank N.A. acquired a new position in shares of Syneos Health in the 1st quarter valued at $224,000. Teachers Retirement System of The State of Kentucky increased its position in shares of Syneos Health by 40.0% in the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 13,188 shares of the company’s stock valued at $899,000 after acquiring an additional 3,765 shares during the period. Finally, Norges Bank acquired a new position in shares of Syneos Health in the 4th quarter valued at $50,763,000. Institutional investors own 99.90% of the company’s stock.
About Syneos Health
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.
Recommended Story: How Do Front-End Loads Impact an Investment?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.